Tomonori Hirashima
Tomonori Hirashima publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Molecular Biology, on topics such as Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment and Lung Cancer Research Studies.
- World rank
- #1,343,240 of 7,710,434 ranked researchers
- Rank in Japan
- #20,399 of 383,136
- Works
- 216
- Citations
- 13k
- Citations per work
- 61.1
What does Tomonori Hirashima research?
Tomonori Hirashima's work is mostly in Medicine (76%), Biochemistry, Genetics and Molecular Biology (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences16476.1%
- Medicine16476.1%
- Everything else4319.9%
- Life Sciences94.0%
- 1Pulmonary and Respiratory Medicine42% of their works
- 2Oncology26% of their works
- 3Molecular Biology4% of their works
- 4Surgery3% of their works
- 5Radiology, Nuclear Medicine and Imaging3% of their works
- 6Epidemiology2% of their works
Research topics
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Medical Imaging and Pathology Studies
- Pleural and Pulmonary Diseases
Which keywords describe Tomonori Hirashima's research?
The keywords of their largest research topics: Clinical Trials, Targeted Therapy, Chemotherapy, ALK Inhibitors, EGFR Mutations, CT Screening, Lung Cancer and Genomic Profiles.
- Pulmonary Alveolar Microlithiasis
- Empyema
- Fibrosis
- Cetuximab
- Immune Checkpoint Blockade
- Genomic Profiles
- CT Screening
- ALK Inhibitors
- Targeted Therapy
- Clinical Trials
- Chemotherapy
- EGFR Mutations
- Lung Cancer
- Small-Cell Lung Cancer
- PD-1 and PD-L1
- KRAS Mutations
- Idiopathic Pulmonary Fibrosis
- Pleural Effusion
- Pulmonary Sclerosing Hemangioma
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Clinical Trials1542 topics
- Targeted Therapy1542 topics
- Chemotherapy1483 topics
- ALK Inhibitors1051 topic
- EGFR Mutations1051 topic
- CT Screening711 topic
- Lung Cancer711 topic
- Genomic Profiles491 topic
- Small-Cell Lung Cancer491 topic
- Immune Checkpoint Blockade351 topic
- PD-1 and PD-L1351 topic
- Cetuximab281 topic
- KRAS Mutations281 topic
- Fibrosis181 topic
- Idiopathic Pulmonary Fibrosis181 topic
- Empyema141 topic
- Pleural Effusion141 topic
- Pulmonary Alveolar Microlithiasis141 topic
- Pulmonary Sclerosing Hemangioma141 topic
Where does Tomonori Hirashima work?
Tomonori Hirashima's main affiliation in the publication record is Osaka Prefectural Medical Center, Japan.
How many publications and citations does Tomonori Hirashima have?
OpenAlex counts 216 works and 13,188 citations for Tomonori Hirashima, an h-index of 40, ranking #1,343,240 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Tomonori Hirashima. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.